Meta-analysis of the efficacy and safety of clopidogrel plus aspirin as compared to antiplatelet monotherapy for the prevention of vascular events
ADK Bowry, MA Brookhart, NK Choudhry - The American journal of …, 2008 - Elsevier
Antiplatelet agents are central to the treatment and prevention of cardiovascular disease.
Although aspirin is the most widely used agent, randomized trials have assessed whether …
Although aspirin is the most widely used agent, randomized trials have assessed whether …
Effect of 1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving …
H Watanabe, T Domei, T Morimoto, M Natsuaki… - Jama, 2019 - jamanetwork.com
Importance Very short mandatory dual antiplatelet therapy (DAPT) after percutaneous
coronary intervention (PCI) with a drug-eluting stent may be an attractive option. Objective …
coronary intervention (PCI) with a drug-eluting stent may be an attractive option. Objective …
The Safety and Efficacy of Aspirin Discontinuation on a Background of a P2Y12 Inhibitor in Patients After Percutaneous Coronary Intervention: A Systematic Review …
ML O'Donoghue, SA Murphy, MS Sabatine - Circulation, 2020 - Am Heart Assoc
Background: Dual antiplatelet therapy with aspirin and a P2Y12 inhibitor has been shown to
reduce the risk of major adverse cardiovascular events (MACE) compared with aspirin alone …
reduce the risk of major adverse cardiovascular events (MACE) compared with aspirin alone …
Clopidogrel discontinuation after acute coronary syndromes: frequency, predictors and associations with death and myocardial infarction—a hospital registry-primary …
R Boggon, TP van Staa, A Timmis… - European heart …, 2011 - academic.oup.com
Aims Adherence to evidence-based treatments and its consequences after acute myocardial
infarction (MI) are poorly defined. We examined the extent to which clopidogrel treatment …
infarction (MI) are poorly defined. We examined the extent to which clopidogrel treatment …
Elderly patients with acute coronary syndromes managed without revascularization: insights into the safety of long-term dual antiplatelet therapy with reduced-dose …
MT Roe, SG Goodman, EM Ohman, SR Stevens… - Circulation, 2013 - Am Heart Assoc
Background—Dual antiplatelet therapy in older versus younger patients with acute coronary
syndromes is understudied. Low-dose prasugrel (5 mg/d) is recommended for younger …
syndromes is understudied. Low-dose prasugrel (5 mg/d) is recommended for younger …
[HTML][HTML] Cardiovascular outcomes after a change in prescription policy for clopidogrel
CA Jackevicius, JV Tu, V Demers, M Melo… - … England Journal of …, 2008 - Mass Medical Soc
Background Drug-reimbursement policies may have an adverse effect on patient outcomes
if they interfere with timely access to efficacious medications for acute medical conditions …
if they interfere with timely access to efficacious medications for acute medical conditions …